Replimune Group, Inc. 7R8.F Stock
Replimune Group, Inc. Price Chart
Replimune Group, Inc. 7R8.F Financial and Trading Overview
| Replimune Group, Inc. stock price | 5.4 EUR |
| Previous Close | 17.5 EUR |
| Open | 17.5 EUR |
| Bid | 21.8 EUR x 0 |
| Ask | 22.2 EUR x 0 |
| Day's Range | 17.5 - 17.5 EUR |
| 52 Week Range | 13.3 - 23.4 EUR |
| Volume | 125 EUR |
| Avg. Volume | 2 EUR |
| Market Cap | 1.26B EUR |
| Beta (5Y Monthly) | 1.644102 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -2.98 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 55.22 EUR |
7R8.F Valuation Measures
| Enterprise Value | 488.45M EUR |
| Trailing P/E | N/A |
| Forward P/E | -7.0281124 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | N/A |
| Price/Book (mrq) | 1.7860787 |
| Enterprise Value/Revenue | N/A |
| Enterprise Value/EBITDA | -2.844 |
Trading Information
Replimune Group, Inc. Stock Price History
| Beta (5Y Monthly) | 1.644102 |
| 52-Week Change | 31.57% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 23.4 EUR |
| 52 Week Low | 13.3 EUR |
| 50-Day Moving Average | 16.44 EUR |
| 200-Day Moving Average | 17.87 EUR |
7R8.F Share Statistics
| Avg. Volume (3 month) | 2 EUR |
| Avg. Daily Volume (10-Days) | 0 EUR |
| Shares Outstanding | 57.78M |
| Float | 42.31M |
| Short Ratio | N/A |
| % Held by Insiders | 8.47% |
| % Held by Institutions | 87.32% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | March 31, 2023 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | March 31, 2024 |
Profitability
| Profit Margin | 0% |
| Operating Margin (ttm) | 0% |
| Gross Margin | 0% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -19.65% |
| Return on Equity (ttm) | -36.064% |
Income Statement
| Revenue (ttm) | N/A |
| Revenue Per Share (ttm) | N/A |
| Quarterly Revenue Growth (yoy) | N/A |
| Gross Profit (ttm) | N/A |
| EBITDA | -171719008 EUR |
| Net Income Avi to Common (ttm) | -174284000 EUR |
| Diluted EPS (ttm) | -2.78 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 583.39M EUR |
| Total Cash Per Share (mrq) | 10.1 EUR |
| Total Debt (mrq) | 60.76M EUR |
| Total Debt/Equity (mrq) | 10.94 EUR |
| Current Ratio (mrq) | 17.52 |
| Book Value Per Share (mrq) | 9.798 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -128050000 EUR |
| Levered Free Cash Flow (ttm) | -71096752 EUR |
Profile of Replimune Group, Inc.
| Country | Germany |
| State | MA |
| City | Woburn |
| Address | 500 Unicorn Park Drive |
| ZIP | 01801 |
| Phone | 781 222 9600 |
| Website | https://www.replimune.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 284 |
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Q&A For Replimune Group, Inc. Stock
What is a current 7R8.F stock price?
Replimune Group, Inc. 7R8.F stock price today per share is 5.4 EUR.
How to purchase Replimune Group, Inc. stock?
You can buy 7R8.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Replimune Group, Inc.?
The stock symbol or ticker of Replimune Group, Inc. is 7R8.F.
Which industry does the Replimune Group, Inc. company belong to?
The Replimune Group, Inc. industry is Biotechnology.
How many shares does Replimune Group, Inc. have in circulation?
The max supply of Replimune Group, Inc. shares is 61.42M.
What is Replimune Group, Inc. Price to Earnings Ratio (PE Ratio)?
Replimune Group, Inc. PE Ratio is now.
What was Replimune Group, Inc. earnings per share over the trailing 12 months (TTM)?
Replimune Group, Inc. EPS is -2.98 EUR over the trailing 12 months.
Which sector does the Replimune Group, Inc. company belong to?
The Replimune Group, Inc. sector is Healthcare.